Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Announces First Subject Dosed in Multi-Dose PK Study for Its Oral Product Candidate for the Prevention of Pre-Term Birth

SALT LAKE CITY, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the first subject dosed in its multi-dose PK dose finding clinical...
September 22, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine to Present at Ladenburg Thalmann 2015 Healthcare Conference

SALT LAKE CITY, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
August 31, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Submits New Drug Application to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021

SALT LAKE CITY, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has submitted a 505(b)(2) New Drug Application ("NDA") to the...
August 11, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Announces Financial and Operational Results for the Second Quarter of 2015

SALT LAKE CITY, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2015, as well as...
August 05, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine to Present at 35th Annual Canaccord Genuity Growth Conference

SALT LAKE CITY, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
June 29, 2015 16:00 ET | Source: Lipocine Inc.

Lipocine's Oral Testosterone Well Tolerated in Phase 3 Study

LPCN 1021 was well tolerated during 52 weeks of dosing No reported hepatic, cardiac or drug-related serious adverse events ("SAEs") Overall adverse event ("AE") profile for LPCN 1021 was...
June 16, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine to Present at the JMP Securities Life Sciences Conference

SALT LAKE CITY, June 16, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown,...
June 15, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Announces Successful Completion of Food Effect Study for LPCN 1021, an Oral Testosterone Product Candidate

Consistent and predictable therapeutic levels of testosterone when administered with a meal No significant sensitivity to meal fat content SALT LAKE CITY, June 15, 2015 (GLOBE NEWSWIRE)...
June 08, 2015 09:00 ET | Source: Lipocine Inc.

Lipocine Announces Development Plans for LPCN 1107

SALT LAKE CITY, June 8, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced its development plans for LPCN 1107, the company's oral...
June 02, 2015 14:02 ET | Source: Lipocine Inc.

Lipocine Receives FDA Orphan Drug Designation for LPCN 1107, an Oral Product Candidate for the Prevention of Preterm Birth

SALT LAKE CITY, June 2, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has granted orphan...